ICON PLC (ICLR)vsIDEXX Laboratories Inc (IDXX)
ICLR
ICON PLC
$169.31
+2.18%
HEALTHCARE · Cap: $12.22B
IDXX
IDEXX Laboratories Inc
$504.70
-0.36%
HEALTHCARE · Cap: $40.98B
Smart Verdict
WallStSmart Research — data-driven comparison
ICON PLC generates 82% more annual revenue ($8.29B vs $4.55B). IDXX leads profitability with a 25.0% profit margin vs 0.3%. ICLR appears more attractively valued with a PEG of 0.50. IDXX earns a higher WallStSmart Score of 63/100 (C+).
ICLR
Buy51
out of 100
Grade: C-
IDXX
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+61.0%
Fair Value
$341.51
Current Price
$169.31
$172.20 discount
Margin of Safety
-48.7%
Fair Value
$436.26
Current Price
$504.70
$68.44 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Every $100 of equity generates 71 in profit
Strong operational efficiency at 35.0%
Safe zone — low bankruptcy risk
Keeps 25 of every $100 in revenue as profit
Areas to Watch
1.2% revenue growth
Distress zone — elevated risk
ROE of 0.7% — below average capital efficiency
0.3% margin — thin
Premium valuation, high expectations priced in
Expensive relative to growth rate
Trading at 24.7x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ICLR
The strongest argument for ICLR centers on PEG Ratio, Price/Book. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bull Case : IDXX
The strongest argument for IDXX centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 25.0% and operating margin at 35.0%.
Bear Case : ICLR
The primary concerns for ICLR are Revenue Growth, Altman Z-Score, Return on Equity. A P/E of 247.4x leaves little room for execution misses. Thin 0.3% margins leave little buffer for downturns.
Bear Case : IDXX
The primary concerns for IDXX are P/E Ratio, PEG Ratio, Price/Book.
Key Dynamics to Monitor
ICLR profiles as a value stock while IDXX is a mature play — different risk/reward profiles.
IDXX carries more volatility with a beta of 1.54 — expect wider price swings.
IDXX is growing revenue faster at 9.7% — sustainability is the question.
IDXX generates stronger free cash flow (323M), providing more financial flexibility.
Bottom Line
IDXX scores higher overall (63/100 vs 51/100), backed by strong 25.0% margins. ICLR offers better value entry with a 61.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ICON PLC
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
ICON Public Limited Company, a clinical research organization, provides outsourced marketing and development services in Ireland, the rest of Europe, the United States and internationally. The company is headquartered in Dublin, Ireland.
IDEXX Laboratories Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?